Research progress of esophageal cancer mouse models

doi:10.3760/cma.j.issn.1673-422X.2013.12.011

Abstract

Abstract: he esophageal cancer mouse models have three categories: chemical carcinogenesis model, xenograft tumor model and genetic engineering model. Chemical carcinogenesis model can simulate well the pathological processes of human esophageal cancer and is prepared simply. Xenograft tumor model is currently the most commonly used esophageal cancer animal model, which has advantages of rapid tumor formation, higher tumor formation rate and lower cost. Genetic engineering model involves mainly p53, Cyclin D1, Brca1 and p120ctn, and it helps to understand the biological characteristics of tumors, but it is expensive and the preparation time is long.

Key words: Esophageal neoplasms, Mice, Disease models, animal, Genetic engineering

MA Wei, WANG Kai, CHENG Yu-Feng. Research progress of esophageal cancer mouse models[J]. Journal of International Oncology, 2013, 40(12): 915-918.

References

［1］ Cheon DJ, Orsulic S. Mouse models of cancer. Annu Rev Pathol, 2011, 6: 95119. ［2］ Garrels W, Ivics Z, Kues WA. Precision genetic engineering in large mammals. Trends Biotechnol, 2012, 30(7): 386393. ［3］ Stepanov I, Knezevich A, Zhang L, et al. Carcinogenic tobaccospecific Nnitrosamines in US cigarettes: three decades of remarkable neglect by the tobacco industry. Tob Control, 2012, 21(1): 4448. ［4］李晶, 于大海, 卿海云, 等. 4硝基喹啉1氧化物饮水法构建BALB/C小鼠胃癌及食管癌模型. 中华实验外科杂志, 2011, 28(9): 1411. ［5］陈慧, 高鑫, 李刚, 等. 4NQO诱发C57BL/6小鼠舌癌及食管鳞状细胞癌模型的建立. 苏州大学学报（医学版）, 2010, 30(5): 972974, 986, 1126. ［6］ Sun Z, Guan X, Li N, et al. Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncol, 2010, 46(2): 105110. ［7］ Liao HY, Wang GP, Gu LJ, et al. HIF1alpha siRNA and cisplatin in combination suppress tumor growth in a nude mice model of esophageal squamous cell carcinoma. Asian Pac J Cancer Prev, 2012, 13(2): 473477. ［8］ Ma J, Zhang J, Ma Y, et al. Adenovirusmediated RhoA shRNA suppresses growth of esophageal squamous cell carcinoma cells in vitro and in vivo. Med Oncol, 2012, 29(1): 119126. ［9］ Crescenzi M, Persano L, Esposito G, et al. Vandetanib improves antitumor effects of L19mTNFalpha in xenograft models of esophageal cancer. Clin Cancer Res, 2011, 17(3): 447458. ［10］ Habibollahi P, Figueiredo JL, Heidari P, et al. Optical imaging with a cathepsin B activated probe for the enhanced detection of esophageal adenocarcinoma by dual channel fluorescent upper GI endoscopy. Theranostics, 2012, 2(2): 227234. ［11］ Rivlin N, Brosh R, Oren M, et al. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer, 2011, 2(4): 466474. ［12］ Lima CR, Rabelo RE, Vulcani VA, et al. P53 gene: major mutations in neoplasias and anticancer gene therapy. Ciência Rural, 2012, 42(5): 845853. ［13］ Zhang Z, Wang Y, Yao R, et al. p53 Transgenic mice are highly susceptible to 4nitroquinoline1oxideinduced oral cancer. Mol Cancer Res, 2006, 4(6): 401410. ［14］ Liu B, Ren Z, Shi Y, et al. Activation of signal transducers and activators of transcription 3 and overexpression of its target gene CyclinD1 in laryngeal carcinomas. Laryngoscope, 2008, 118(11): 19761980. ［15］ Opitz OG, Harada H, Suliman Y, et al. A mouse model of human oralesophageal cancer. J Clin Invest, 2002, 110(6): 761769. ［16］ Wang L, Yang HY, Zheng YQ. Personalized medicine of esophageal cancer. J Cancer Res Ther, 2012, 8(3): 343347. ［17］ Cao L, Xu X, Cao LL, et al. Absence of fulllength Brca1 sensitizes mice to oxidative stress and carcinogeninduced tumorigenesis in the esophagus and forestomach. Carcinogenesis, 2007, 28(7): 14011407. ［18］ Stairs DB, Bayne LJ, Rhoades B, et al. Deletion of p120catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell, 2011, 19(4): 470483. ［19］ Liu M, Hicklin D. Tumor models in cancer research. 2nd ed. New York: Human Press, 2011: 99124. ［20］ Sun SJ, Feng L, Zhao GQ, et al. HAX1 promotes the chemoresistance, invasion, and tumorigenicity of esophageal squamous carcinoma cells. Dig Dis Sci, 2012, 57(7): 18381846. ［21］ Huang SM, Hsu PC, Chen MY, et al. The novel indole compound SK228 induces apoptosis and FAK/Paxillin disruption in tumor cell lines and inhibits growth of tumor graft in the nude mouse. Int J Cancer, 2012, 131(3): 722732. ［22］ Gong JH, Liu XJ, Li Y, et al. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. Cancer Chemother Pharmacol, 2012, 69(5): 13231332. ［23］ Wong GS, Habibollahi P, Heidari P, et al. Optical imaging of periostin enables early endoscopic detection and characterization of esophageal cancer in mice. Gastroenterology, 2013, 144(2): 294297. ［24］ Bruyère C, Lonez C, Duray A, et al. Considering temozolomide as a novel potential treatment for esophageal cancer. Cancer, 2011, 117(9): 20042016.

[1]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[2]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[3]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[4]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[5]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[6]	Ji Shiyu, Zhang Mingxin, Xie Huahong, Bai Yuan, Wang Tong. Observation on the efficacy of different stents in the treatment of patients with advanced esophageal cancer [J]. Journal of International Oncology, 2023, 50(2): 76-81.
[7]	Gong Heyi, Yi Yan, Zhang Jian, Li Baosheng. Management strategies for locally advanced operable esophageal carcinoma achieving clinical complete response after neoadjuvant chemoradiotherapy [J]. Journal of International Oncology, 2023, 50(12): 745-750.
[8]	Wu Puyuan, Qi Liang, Wang Tao, Shi Minke, Sun Yuwei, Wang Lifeng, Liu Baorui, Yan Jing, Ren Wei. Efficacy of postoperative radiotherapy based on modified clinical target volume according to high-frequency recurrence regions in patients with esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(8): 464-472.
[9]	Xia Lingling, Chen Yongshun, Li Bin, Ning Tingting, Zhang Caiyutian. Comparison of safety and efficacy between chemoradiotherapy and chemotherapy after R0 resection in pN₊ esophageal squamous cell carcinoma patients [J]. Journal of International Oncology, 2022, 49(6): 334-339.
[10]	Ye Qian, Ling Zhi, Liu Shenxiang, Lu Guotao, Yin Xudong. Effects of sarcopenia on the clinical efficacy and prognosis of radical radiotherapy in elderly patients with esophageal cancer [J]. Journal of International Oncology, 2022, 49(4): 199-205.
[11]	Zhou Jianfeng, Wang Tiejun. Targeted therapy and immunotherapy of esophageal cancer [J]. Journal of International Oncology, 2022, 49(4): 237-242.
[12]	Liu Jia, Ge Xiaolin, Di Xiaoke, Shi Yujing, Zeng Yuting. Efficacy analysis of Xiyanping injection on prevention of radioactive esophagitis [J]. Journal of International Oncology, 2022, 49(3): 146-150.
[13]	Zhang Junpeng, Yu Yanyan, Li Baosheng. Mechanism of lncRNA and circRNA regulating the sensitivity of radiotherapy and chemotherapy in esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(3): 185-189.
[14]	Geng Hui, Hu Fengchao, Lu Hongchao, Guo Jungang, Qi Zengping. Effects of TPF regimen and IMRT on immune function and survival prognosis of patients with advanced esophageal cancer [J]. Journal of International Oncology, 2022, 49(2): 84-88.
[15]	Guo Xinwei, Zhang Han, Ye Hongxun, Liu Yangchen, Ji Shengjun, Zhou Shaobing, Zhou Juying. Influence of preoperative Naples prognostic score on prognosis of patients with thoracic esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2022, 49(2): 89-94.